Y0002098
索拉非尼
European Pharmacopoeia (EP) Reference Standard
别名:
4- [4-[[[[4-氯-3-（三氟甲基）苯基]氨基]羰基]氨基]苯氧基] -N-甲基-2-吡啶甲酰胺
等级
pharmaceutical primary standard
API类
sorafenib
制造商/商品名称
EDQM
应用
pharmaceutical
包装形式
neat
储存温度
2-8°C
SMILES字符串
FC(F)(F)c1c(ccc(c1)NC(=O)Nc2ccc(cc2)Oc3cc(ncc3)C(=O)NC)Cl
InChI
1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
InChI key
MLDQJTXFUGDVEO-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
本品按现行药典规定交付。该产品的所有支持信息，包括SDS和任何产品信息宣传页均由药典发行机构制定并发布。如需更多信息和支持，请见现行药典的网站。
应用
索拉非尼（EP参考标准品）仅用于欧洲药典中明确规定的实验室测试用途。
包装
本品按照现行药典要求提供。有关当前单位数量，请见EDQM 参考目录。
其他说明
可能适用相应的销售限制。
警示用语：
Danger
危险分类
Aquatic Acute 1 - Aquatic Chronic 1 - Lact. - Repr. 1B - STOT RE 1
储存分类代码
6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Yiliang Wang et al.
Journal of nanobiotechnology, 22(1), 473-473 (2024-08-13)
Hepatocellular carcinoma (HCC) is a highly malignant tumor known for its hypoxic environment, which contributes to resistance against the anticancer drug Sorafenib (SF). Addressing SF resistance in HCC requires innovative strategies to improve tumor oxygenation and effectively deliver therapeutics. In
Ye Kuang et al.
Cancer medicine, 12(6), 7222-7233 (2022-11-25)
Hepatocellular carcinoma (HCC) is a primary liver cancer with high mortality. The long-term use of sorafenib, a targeted drug for hepatocellular carcinoma, will lead to drug resistance, and patients are prone to cancer metastasis, the molecular mechanism of which is
Baoxin Zhao et al.
Virologica Sinica, 38(5), 680-689 (2023-06-19)
Chronic hepatitis B virus (HBV) infection is one of the leading causes of hepatocellular carcinoma (HCC). The HBV genome is prone to mutate and several variants are closely related to the malignant transformation of liver disease. G1896A mutation (G to
Zhong Wan et al.
Aging, 12(18), 18192-18208 (2020-10-07)
We investigated MAPK14-dependent resistance to sorafenib in hepatocellular carcinoma (HCC). Bioinformatics analysis and dual luciferase reporter assays in HCC cell lines showed that miR-216a-3p directly binds to the 3'UTR of MAPK14 mRNA and downregulates MAPK14 protein expression. Consequently, miR-216a-3p expression
Su-Hong Chen et al.
Experimental and therapeutic medicine, 23(3), 232-232 (2022-03-01)
Sorafenib is currently used to treat hepatocellular carcinoma (HCC). However, the development of chemoresistance to sorafenib is a major limitation for sorafenib-based therapy in patients with HCC. In the present study, the effect of the combination therapy of sorafenib and
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持